LLY

1,132.46

+0.85%↑

JNJ

232.42

+1.84%↑

ABBV

226.36

+0.8%↑

UNH

401.28

+0.92%↑

MRK

121.03

+0.7%↑

LLY

1,132.46

+0.85%↑

JNJ

232.42

+1.84%↑

ABBV

226.36

+0.8%↑

UNH

401.28

+0.92%↑

MRK

121.03

+0.7%↑

LLY

1,132.46

+0.85%↑

JNJ

232.42

+1.84%↑

ABBV

226.36

+0.8%↑

UNH

401.28

+0.92%↑

MRK

121.03

+0.7%↑

LLY

1,132.46

+0.85%↑

JNJ

232.42

+1.84%↑

ABBV

226.36

+0.8%↑

UNH

401.28

+0.92%↑

MRK

121.03

+0.7%↑

LLY

1,132.46

+0.85%↑

JNJ

232.42

+1.84%↑

ABBV

226.36

+0.8%↑

UNH

401.28

+0.92%↑

MRK

121.03

+0.7%↑

Home・Akcijų sąrašas・MannKind Corp

MannKind Corp

Atidarymo kaina

SektoriusSveikatos priežiūra

3.4 -2.58

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.4

Max

3.52

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-671K -17M
Pardavimai	-22M 90M
P/E Sektoriaus vid.	140.5 49.888
Pelnas, tenkantis vienai akcijai	-0.02
Pelno marža	-18.431
Darbuotojai	591
EBITDA	5.9M 3.4M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+131.53% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	223M 1.1B
Ankstesnė atidarymo kaina	5.98
Ankstesnė uždarymo kaina	3.4

Naujienos nuotaikos

By Acuity

47%

53%

150 / 344 reitingas Healthcare

MannKind Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-04 21:51; UTC

Pagrindinės rinkos jėgos

Merlin Shares Rally After Defense Department's Design Review Wraps

2026-06-04 23:46; UTC

Rinkos pokalbiai

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

2026-06-04 23:44; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

2026-06-04 23:42; UTC

Įsigijimai, susijungimai, perėmimai

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

2026-06-04 23:41; UTC

Įsigijimai, susijungimai, perėmimai

Energy Resources of Australia to Enter Trading Halt

2026-06-04 23:34; UTC

Rinkos pokalbiai

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

2026-06-04 23:31; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-06-04 23:08; UTC

Rinkos pokalbiai

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

2026-06-04 22:41; UTC

Rinkos pokalbiai

Australia Shares Set to Rise at the Open -- Market Talk

2026-06-04 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-04 20:44; UTC

Įsigijimai, susijungimai, perėmimai

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

2026-06-04 20:16; UTC

Rinkos pokalbiai

Mexican Demand Indicators Show Signs of Life -- Market Talk

2026-06-04 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

2026-06-04 19:46; UTC

Rinkos pokalbiai

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

2026-06-04 19:38; UTC

Rinkos pokalbiai

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

2026-06-04 19:30; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

2026-06-04 18:47; UTC

Įsigijimai, susijungimai, perėmimai

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

2026-06-04 18:38; UTC

Uždarbis

Money Quote: Tech Weakness in Context -- WSJ

2026-06-04 18:24; UTC

Uždarbis

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-04 17:09; UTC

Rinkos pokalbiai

Retest of $55k Seen Possible for Bitcoin -- Market Talk

2026-06-04 16:58; UTC

Uždarbis

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

2026-06-04 16:46; UTC

Rinkos pokalbiai

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

2026-06-04 16:38; UTC

Uždarbis

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

2026-06-04 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-04 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-06-04 16:13; UTC

Rinkos pokalbiai

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

2026-06-04 16:11; UTC

Rinkos pokalbiai

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

2026-06-04 15:56; UTC

Rinkos pokalbiai

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Akcijų palyginimas

Kainos pokytis

MannKind Corp Prognozė

Kainos tikslas

By TipRanks

131.53% į viršų

12 mėnesių prognozė

Vidutinis 8.15 USD 131.53%

Aukščiausias 11 USD

Žemiausias 4.75 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines MannKind Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių MannKind Corp akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

150 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.